Results 171 to 180 of about 1,793,389 (302)

Advances in antiviral drug design.

, 1999
Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections.
De Clercq, Erik.
core  

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Treatment guidelines for Hepatitis C in Spain

Revista Española de Sanidad Penitenciaria
The discovery of new orally administered drugs that can block different targets of the replication cycle of the hepatitis C virus (HCV) with major antiviral activity, has revolutionized treatment of this infection and relegated interferon-based ...
M. Crespo-Casal
doaj  

Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas. [PDF]

ChemMedChem
Minneci M, Farkaš B, Rahman A, Kempf A, Nehlmeier I, Pöhlmann S, Rozas I.   +6 more
europepmc   +1 more source

Probiotic spore‐based bioresponsive drug delivery for reversing inflammatory bowel disease and its associated anxiety and depression

BMEMat, EarlyView.
A probiotic spore‐based drug delivery system (BCS‐Que@ApNPs) provides excellent targeted delivery, bioresponsive drug release, and long‐term retention (over 48 h), making it suitable for oral treatment of inflammatory bowel disease and its associated anxiety and depression.
Qingling Song, Beiyang Xue, Yao Li, Chuangxi Zhou, Junfei Yang, Yunfei Li, Lingwen Ding, Yun Zhang, Hongjuan Zhao, Lei Wang   +9 more
wiley   +1 more source

Special Issue "Advances in Antiviral Agents Against SARS-CoV-2 and Its Variants" 2nd Edition. [PDF]

Viruses
Esposito F.
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

The Emerging Promise of Pentacyclic Triterpenoid Derivatives as Novel Antiviral Agents Against SARS-CoV-2 Variants. [PDF]

Molecules
Wan X, Cui X, Liang K, Huang J, Chen K, Chen W, Song G.   +6 more
europepmc   +1 more source

Selected Plant Triterpenoids and Their Derivatives as Antiviral Agents. [PDF]

Molecules, 2023
Wimmerová M, Bildziukevich U, Wimmer Z.
europepmc   +1 more source

4′‐ThioRNA Substitution and Sense‐Strand Segmentation for the Design of Functional Fully Modified siRNAs Targeting SARS‐CoV‐2

Chemistry – A European Journal, EarlyView.
4′‐ThioRNA was broadly tolerated across multiple positions in SARS‐CoV‐2‐targeting siRNAs, but full 4'‐thio modification of both strands caused a reduction in RNAi activity. Sense‐strand segmentation improved RNAi and antiviral activity, particularly when the nick was located at position 10 from the 5′‐end of the sense strand, thereby unlocking the ...
Yuhei Nogi, Jun Tsukimoto, Noriko Saito‐Tarashima, Takaaki Koma, Masako Nomaguchi, Noriaki Minakawa   +5 more
wiley   +1 more source